ALMS was a well-designed, randomized, controlled trial that included 370 patients with systemic lupus erythematosus (SLE) and class III, IV, or V nephritis. Like every recent major trial of new ...

Amit Saxena, MD, discusses how evidence-based guidelines from ACR and KDIGO have evolved to shape lupus nephritis treatment approaches, emphasizing their critical role in standardizing patient care ...

Importantly, the guidelines suggest that steroids should be rapidly tapered to < 5 mg/day by six months ... adult patients with active lupus nephritis. Aurinia is also developing AUR200, a ...

Conventional lupus nephritis (LN) treatment based on cyclophosphamide ... [1] It usually arises within 5–10 years of diagnosis and its prevalence varies depending on the population and the ...

Kidney problems are common in people with lupus. Sometimes, lupus can cause a type of kidney disease called lupus nephritis. Lupus nephritis can cause kidney failure. But greater access to therapies ...

as an option for adults at the more severe end of the lupus nephritis spectrum, in other words, those with class 3, 4, and 5 disease, according to the guidance. The drug was approved by the ...

The Lupus Foundation of America (LFA) is proud to honor two exceptional lupus researchers at the 2024 Evelyn V. Hess ...

Lupus nephritis is an inflammatory kidney disease (glomerulonephritis) that develops in patients with systemic lupus erythematosus (SLE). In patients with SLE, the immune system is not properly ...

Regular assessment of renal function, proteinuria, and serological markers is crucial for monitoring lupus nephritis progression and treatment response. Long-term follow-up data offer valuable ...

Objective Lupus nephritis (LN) is a major cause of morbidity and mortality, affecting up to 60% of patients with systemic lupus erythematosus (SLE). The perspectives of patients with SLE have been ...